Giving anemia a boost with inhibitors of prolyl hydroxylase.


There is much current interest in the development of inhibitors of the prolyl hydroxylase (PHD) enzymes that regulate the hypoxia-inducible transcription factor (HIF), which in turn stimulates the production of erythropoietin and ultimately red blood cells, as a treatment for anemia. A recent paper reports the synthesis and evaluation of a novel class of potent spirohydantoin-based pan-PHD inhibitors for this purpose. The paper is an exemplar of drug development from high-throughput screen to clinical candidate.

DOI: 10.1021/jm300314a

Cite this paper

@article{Denny2012GivingAA, title={Giving anemia a boost with inhibitors of prolyl hydroxylase.}, author={William A. Denny}, journal={Journal of medicinal chemistry}, year={2012}, volume={55 7}, pages={2943-4} }